Chronic cavitary pulmonary sporotrichosis: efficacy of oral itraconazole.

Abstract

The small number of patients suffering from pulmonary involvement with Sporothrix schenckii has prevented prospective controlled studies that could determine the optimal therapy for this chronic infection. The clinician's ability to determine the best medical treatment for chronic cavitary pulmonary sporotrichosis is also tempered by the limited use of newer azole antifungal agents in this disorder as well as the relative lack of efficacy reported with older therapies. We present a 50-year-old male with primary pulmonary sporotrichosis whose chronic cavitary disease responded to oral itraconazole.

• Authors: J Ramirez, R P Byrd Jr, T M Roy
• Journal: The Journal of the Kentucky Medical Association (J Ky Med Assoc) Vol. 96 Issue 3 Pg. 103-5 (Mar 1998) ISSN: 0023-0294 [Print] United States
• PMID: 9529831 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Fungal
• Antifungal Agents
• Itraconazole

Topics

• Administration, Oral
• Antibodies, Fungal (isolation & purification)
• Antifungal Agents (administration & dosage)
• Chronic Disease
• Humans
• Itraconazole (administration & dosage)
• Lung Diseases, Fungal (diagnostic imaging, drug therapy, immunology)
• Male
• Middle Aged
• Sporothrix (immunology)
• Sporotrichosis (diagnostic imaging, drug therapy, immunology)
• Tomography, X-Ray Computed